Related Experiment Video
Updated: Jun 19, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Life expectancy in Alzheimer's disease (AD)
O Zanetti1, S B Solerte, F Cantoni
1UO Alzheimer-Memory Clinic, IRCCS Centra S. Giovanni di Dio Fatebenefratelli, Brescia, Italy. ozanetti@fatebenefratelli.it
Archives of Gerontology and Geriatrics
|October 20, 2009
Summary
Life expectancy for Alzheimer's Disease (AD) patients varies significantly, with age at diagnosis being a key predictor. Early diagnosis in the 60s and 70s offers a longer prognosis compared to later diagnoses in the 90s.
Area of Science:
- Neurology
- Gerontology
- Public Health
Background:
- Alzheimer's Disease (AD) significantly shortens life expectancy, impacting patients, families, and healthcare planning.
- Accurate prognosis is crucial for improving care plans and aiding clinical decision-making, especially in moderate-to-severe AD stages.
- Current predictive information for clinicians is limited, highlighting the need for better understanding of AD progression.
Purpose of the Study:
- To investigate factors influencing survival rates in Alzheimer's Disease patients.
- To provide clinicians with more reliable data for prognostic assessments.
- To empower patients and families with better knowledge of life expectancy.
Main Methods:
- Review of existing studies identifying predictive factors for life expectancy in AD.
- Analysis of the impact of age at diagnosis on survival.
- Comparison of AD progression with other dementia types exhibiting distinct symptoms.
Main Results:
- Age at diagnosis is the primary predictor of life expectancy in Alzheimer's Disease.
- Patients diagnosed in their 60s and 70s have a median life span of 7-10 years.
- Patients diagnosed in their 90s have a life expectancy of approximately 3 years or less.
- Dementias with psychiatric-behavioral issues or gait impairment may progress faster than typical AD.
Conclusions:
- Prognosis in AD is complex due to numerous influencing variables, making bedside predictions challenging.
- Further research is essential to refine prognostic tools for clinicians.
- Improved understanding of AD survival will aid in daily patient care and caregiver support.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.